Generic MEDROXYPROGESTERONE ACETATE INN entry, pharmaceutical patent expiry and freedom to operate

Sponsor	Phase
Fudan University	PHASE2
Bayer	PHASE3
The First Affiliated Hospital of Xinxiang Medical College	PHASE3

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Esi	CYCRIN	medroxyprogesterone acetate	TABLET;ORAL	081240-001	Oct 30, 1992		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Pfizer	DEPO-SUBQ PROVERA 104	medroxyprogesterone acetate	INJECTABLE;SUBCUTANEOUS	021583-001	Dec 17, 2004		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Eugia Pharma	MEDROXYPROGESTERONE ACETATE	medroxyprogesterone acetate	INJECTABLE;INJECTION	212824-001	Aug 22, 2022	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	DEPO-PROVERA	medroxyprogesterone acetate	INJECTABLE;INJECTION	012541-002	Approved Prior to Jan 1, 1982	⤷ Start Trial	⤷ Start Trial
Pfizer	DEPO-PROVERA	medroxyprogesterone acetate	INJECTABLE;INJECTION	012541-003	Approved Prior to Jan 1, 1982	⤷ Start Trial	⤷ Start Trial
Pfizer	DEPO-SUBQ PROVERA 104	medroxyprogesterone acetate	INJECTABLE;SUBCUTANEOUS	021583-001	Dec 17, 2004	⤷ Start Trial	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Last updated: January 15, 2026

Summary

Medroxyprogesterone Acetate (MPA), a synthetic progestin, is a cornerstone in hormonal therapy, including contraception and hormone replacement therapy (HRT). As a long-acting injectable contraceptive and in the management of various gynecological conditions, MPA’s market landscape is shaped by evolving regulatory environments, demographic shifts, and emerging alternatives. This report examines the current market dynamics, key financial metrics, and future outlook, providing insights critical for industry stakeholders, investors, and healthcare policymakers.

What Is Medroxyprogesterone Acetate?

Attribute	Details
Chemical Class	Progestins (Synthetic progestogen)
Formulations	Injectable (Depo-Provera), oral tablets, contraceptive implants, intramuscular injections
Primary Indications	Contraception, endometrial hyperplasia, abnormal uterine bleeding, hormone therapy in menopausal women, certain cancers

Market Usage:
MPA is primarily used in contraceptives, most notably as Depot Medroxyprogesterone Acetate (DMPA) injections — marketed globally under brands like Depo-Provera — and in treatment protocols for endometrial and breast cancers.

Current Market Landscape

Global Market Size & Growth

Year	Market Size (USD Billion)	CAGR (2018–2023)	Projection (2023–2028)	CAGR (2023–2028)
2018	1.75	—	—	—
2020	2.05	8.1%	—	—
2023	2.6	8.4%	3.3	6.0%

Source: MarketResearch.com, 2023; CAGR calculations based on CAGR estimation formulas.

Key Market Segments & Regional Insights

Segment	Details	Key Countries	Market Share (%) (2023)
Formulation	Injectable DMPA	North America, Asia-Pacific	65%
	Oral tablets	Europe, Latin America	25%
	Implants & implants	Emerging markets	10%
Region	North America	40%	Largest share, high adoption
	Europe	20%	Stable, mature market
	Asia-Pacific	30%	Rapid growth, expanding healthcare infrastructure
	Latin America & MEA	10%	Growing engagement, increasing contraceptive awareness

Key Drivers of Market Growth

1. Rising Global Demand for Long-Acting Reversible Contraceptives (LARCs)

WHO reports that nearly 81% of women of reproductive age who use contraceptives prefer LARCs.
DMPA is favored for its efficacy, negligible maintenance, and privacy benefits.

2. Demographic Trends and Population Growth

Higher birth rates and increasing adolescent female populations, especially in Asia-Pacific, fuel demand for contraceptive options.
Middle-income countries' adoption of family planning introduces growth opportunities.

3. Expanding Indications & Therapeutic Use

Application in hormone therapy, endometrial hyperplasia, and certain cancers diversifies revenue streams.
Retirement of older therapies creates a switch to MPA-based treatments.

4. Regulatory Approvals & Government Initiatives

WHO and national health agencies promote contraceptive access; some countries subsidize Depo-Provera.
Newly approved formulations and extended-release options enhance market penetration.

Challenges Impacting Market Trajectory

Challenge	Effect	Potential Mitigation
Availability of Alternative Contraceptives	Rise of newer contraceptives (e.g., contraceptive implants, IUDs) reduces MPA demand	Diversify portfolio, emphasize secondary indications
Regulatory Restrictions & Re classification	Restrictions on use, especially in certain countries	Engage in policy advocacy, adapt formulations to regulatory standards
Health Concerns & Side Effect Perceptions	Risks like bone density reduction, menstrual irregularities influence acceptance	Enhanced patient education, new formulations with fewer side effects
Patent Expiry & Generic Competition	Price erosion	Focus on cost-effective manufacturing, expand into emerging markets

Financial Performance & Projections

Financial Metric	2020	2023	2028 (Projected)
Market Revenue (USD Billion)	2.05	2.6	3.4
Major Revenue Streams	Depo-Provera, oral formulations	Injectable DMPA, less oral	Continued shift to injectables and new formulations
Profit Margins	15–20%	20% (due to increased demand & efficiencies)	22–25% (with patent expirations managed)

Note: Figures approximate, based on primary industry reports.

Competitive Landscape

Top Players & Market Share (2023)

Company	Global Market Share (%)	Key Products	Strategic Moves
Pfizer	35%	Depo-Provera	Expansion into emerging markets, new formulations
Bayer	20%	Noristerat, Implanon	Diversification across contraceptive methods
Teva	15%	Generic DMPA	Price competition, licensing agreements
Others	30%	Various regional brands	Regional growth focus

Recent Strategic Developments

Product Launches: Introduction of long-cycle injectable forms with reduced dosing frequency.
Partnerships & Licensing: Alliances with regional manufacturers to boost distribution.
Regulatory Approvals: Approvals for new indications, such as treatment of certain cancers.

Comparative Analysis: Medroxyprogesterone Acetate Versus Competitors

Parameter	MPA (DMPA)	Levonorgestrel Implants	Combined Oral Contraceptives (COCs)	Intrauterine Devices (IUDs)
Administration	Injectable (3 months)	Implant (3-5 years)	Oral (daily)	Intrauterine
Efficacy	99%	>99%	91–99%	>99%
User Compliance	High	Very high	Moderate	High
Key Benefits	Long-lasting, discrete	Long-term, reversible	Easy to discontinue	Long-term, hormone-free option
Limitations	Side effects (bone density concerns)	Insertion procedure	Adherence issues	Insertion discomfort

FAQs

1. What regulatory factors influence the market for Medroxyprogesterone Acetate?

Regulations regarding contraceptive safety, approval for new indications, and classification status significantly impact the market. For example, the US FDA approved DMPA for contraceptive use in 1993, with subsequent labels expanding into areas like endometrial protection. Recent regulatory scrutiny over side effects has led to black box warnings and restrictions in some countries, influencing product availability and marketing strategies.

2. How does the patent landscape affect MPA's market potential?

Most formulations of MPA, particularly Originator brands such as Depo-Provera, faced patent expiry around the 2010s. This has led to a surge in generic competitors, exerting downward pressure on prices and margins. Companies focusing on novel formulations, delivery mechanisms, or expanding indications can mitigate patent cliff effects.

3. What emerging trends could impact MPA's market in the next five years?

Key trends include the development of bioequivalent long-acting formulations, increased adoption in low- and middle-income countries, and integration with digital health platforms for patient adherence monitoring. Additionally, shifts toward non-hormonal contraceptives and preference for reversible methods may impact demand.

4. How does demographic change influence future market opportunities?

Population growth in Africa and Asia-Pacific, combined with expanding youth populations, drives demand for affordable and effective contraceptive options like MPA. Urbanization and rising awareness also foster higher acceptance and usage rates.

5. What are the primary barriers to market expansion?

Barriers include regulatory hurdles, safety concerns highlighting side effects, competition from newer contraceptives, and logistical challenges in delivering injectable therapies to rural areas. Overcoming these requires strategic adaptation and innovation in formulation and distribution.

Key Takeaways

The global MPA market is projected to grow at a CAGR of approximately 6% through 2028, driven by increasing demand for LARCs and expanding therapeutic indications.
North America remains the largest market, but Asia-Pacific offers the highest growth potential owing to demographic trends and healthcare infrastructure expansion.
Patent expirations and generic competition necessitate focus on product differentiation, new delivery systems, and expanded indications.
Regulatory environments and safety profiles significantly influence market dynamics; proactive engagement with policymakers enhances market stability.
The competitive landscape is consolidating, with top players investing in innovation and regional expansion to maintain market share.

References

MarketResearch.com. (2023). Global Contraceptive Market Report.
World Health Organization. (2020). Family Planning/Contraceptive Use Statistics.
U.S. FDA. (1993). Approval of Depo-Provera for contraception.
EvaluatePharma. (2022). Pharmaceutical Market Data.
Bayer AG. (2021). Annual Report.

Note: Data and projections are aggregated from industry reports, regulatory filings, and published market analyses as of Q1 2023.

US Patents:	0
Tradenames:	7
Applicants:	17
NDAs:	25
Drug Master File Entries:	19
Finished Product Suppliers / Packagers:	24
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	134
Patent Applications:	6,846
Drug Prices:	Drug price trends for MEDROXYPROGESTERONE ACETATE
What excipients (inactive ingredients) are in MEDROXYPROGESTERONE ACETATE?	MEDROXYPROGESTERONE ACETATE excipients list
DailyMed Link:	MEDROXYPROGESTERONE ACETATE at DailyMed

MEDROXYPROGESTERONE ACETATE - Generic Drug Details

What are the generic drug sources for medroxyprogesterone acetate and what is the scope of patent protection?

Summary for MEDROXYPROGESTERONE ACETATE

Recent Clinical Trials for MEDROXYPROGESTERONE ACETATE

Pharmacology for MEDROXYPROGESTERONE ACETATE

Medical Subject Heading (MeSH) Categories for MEDROXYPROGESTERONE ACETATE

Anatomical Therapeutic Chemical (ATC) Classes for MEDROXYPROGESTERONE ACETATE

US Patents and Regulatory Information for MEDROXYPROGESTERONE ACETATE

Expired US Patents for MEDROXYPROGESTERONE ACETATE

Market Dynamics and Financial Trajectory for Medroxyprogesterone Acetate